Overview

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

Status:
Completed

Trial end date:
2012-06-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron
Solifenacin Succinate